Clinilabs selected for phase II study
New York-based CRO Clinilabs has been selected to conduct a phase II clinical research study of an investigational medication in patients with Major Depressive Disorder.
The trial will examine the effects of an investigational medication in treatment-resistant patients experiencing a current episode of depression. This is Clinilabs’ fifth study in this therapeutic area. Dr. Stephen Murray, Clinilabs’ Chief Medical Officer, said, “Major Depressive Disorder is a debilitating disease that carries with it both emotional and physical symptoms. I am pleased to be involved in a clinical trial that is assessing a novel medication that may combat this condition.”
Enrollment for this study has begun.